FTC Pushes Congress To Pass Drug Settlement Bill
The FTC's Bureau of Competition Director Richard A. Feinstein told a House Judiciary Committee hearing that the settlements now common in U.S. drug industry patent disputes are anti-competitive, and block rapid consumer access to lower-cost generics.
The settlements also impose additional costs on the country's health care system, Feinstein argued.
The FTC strongly backs H.R. 1706, the Protecting Consumer...
To view the full article, register now.